Atossa Therapeutics, Inc. expressed disappointment over the Patent Trial and Appeal Board's ruling deeming all challenged claims of U.S. Patent No. 11,572,334 unpatentable. While Atossa will not ...
Clear strategy & focus: Atossa is concentrating capital on programs and data packages that can enable future regulatory submissions and potential commercialization. Compelling thesis for new investors ...
Atossa Therapeutics Issues Letter to Shareholders Highlighting 2025 Accomplishments and 2026 Outlook
The MarketWatch News Department was not involved in the creation of this content. SEATTLE, Feb. 11, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a ...
Type C FDA Meeting Requested, Update Expected by Year-End 2025 SEATTLE, Sept. 8, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (ATOS) (Nasdaq: ATOS; "Atossa" or the "Company") announced today it has ...
SEATTLE, July 29, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (NASDAQ: ATOS), a clinical-stage biopharmaceutical company developing innovative medicines in oncology, today announced positive ...
・The FDA designation expands Atossa’s investigational therapy into rare pediatric neuromuscular disease. ・The program could become eligible for a Priority Review Voucher upon future approval.
FDA Provides Positive Feedback, Clears Path for Atossa to File IND for (Z)-Endoxifen in Metastatic Breast Cancer; FDA Indicates No Additional Toxicity Studies Required Strong I-SPY2 Results Reinforce ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results